logo

Zealand Pharma A/S (ZEAL)



Trade ZEAL now with
  Date
  Headline
9/4/2020 6:06:58 AM Zealand Pharma Appoints Danilo Verge And David Kendall To Spearhead Medical Affairs Organization
8/3/2020 4:01:26 AM Zealand Pharma Appoints Mads Kronborg As Head Of Investor Relations & Communication
6/24/2020 3:29:26 AM Zealand Says First Patient Dosed In Phase 2 Trial Of GLP-1/glucagon Dual Agonist BI 456906
6/15/2020 2:51:39 AM Zealand Appoints Frank Sanders As President Of Zealand Pharma U.S.
5/26/2020 5:52:51 AM Zealand Pharma Raises Its Share Capital As Consequence Of Exercise Of Employee Warrants
5/14/2020 9:09:56 AM Zealand Pharma Files NDA For Dasiglucagon HypoPal Rescue Pen
4/2/2020 8:39:51 AM Zealand Pharma Completes Acquisition Of Valeritas
3/31/2020 10:08:19 AM Zealand Pharma Submits NDA To FDA For Dasiglucagon HypoPal Rescue Pen For Treatment Of Severe Hypoglycemia
3/30/2020 7:38:38 AM Zealand Report Positive Topline Results From Phase 2 Trial With Dasiglucagon
3/20/2020 11:14:25 AM Valeritas Receives Court Approval Of Sale Of Business To Zealand Pharma
3/20/2020 5:05:19 AM Zealand Pharma Increases Share Capital By A Nominal Amount Of DKK 91,475 Divided Into 91,475 New Shares
2/9/2020 8:26:02 PM Valeritas Commence Voluntary Chapter 11 To Facilitate Value-Maximizing Sale
12/10/2019 3:05:25 AM Beta Bionics Receives FDA Breakthrough Device Designation For ILet Bionic Pancreas System
10/22/2019 6:12:20 AM Zealand Pharma Announces Acquisition Of Encycle Therapeutics
9/24/2019 6:01:47 AM Zealand Pharma Meets Endpoints In Pediatric Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
9/3/2019 2:08:05 AM Boehringer Ingelheim To Begin Phase 2 Development Of GLP-1/glucagon Dual Agonist BI 456906